Clinical trials
catalyst calendar across sponsors →Studies where EVMN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 with posted results
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., Balyasny Asset Management L.P., JANE STREET GROUP, LLC, Holocene Advisors, LP, Squarepoint Ops LLC, +5 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of EVO756 in Adults With MigraineNCT07616128Mean change from baseline in the number of monthly migraine days (MMD)Randomized · Quadruple-masked · Prevention | Phase 2 | Recruiting | Drug: EVO756, Dose 1, EVO756, Dose 2, Placebo | Migraine | 330 | Oct 2027 | ≤ 437 d | 2026-08-10 |
| Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845Percentage change in Eczema Area and Severity Index (EASI) from BaselineRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: EVO756, EVO756, EVO756, Placebo control | Atoptic Dermatitis | 120 | Jul 2026 | — | 2026-05-18 |
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)NCT06873516Mean change from baseline in UAS7Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: EVO756, EVO756, EVO756, Placebo control | Chronic Spontaneous Urticaria | 182 | 2026-05-29actual | — | 2026-07-01 |
| Efficacy Study of EVO301 in Moderate to Severe Atopic DermatitisNCT06723405Eczema Area and Severity Index (EASI)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: EVO301, Placebo | Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis | 71 | 2025-11-17actual | — | 2025-12-04 |
| A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible UrticariaNCT06603220results2026-05-19Safety and TolerabilityOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Oral EVO756 300 mg QD, Oral EVO756 50 mg BID | Chronic Inducible Urticaria | 30 | 2025-05-08actual | — | 2026-05-19 |
| Safety and Efficacy Study of EVO101 Topical Cream in Atopic DermatitisNCT05579899results2025-03-05Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EVO101 | Atopic Dermatitis Eczema | 119 | 2023-07-27actual | — | 2025-03-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19